Comparison of effect on inflammation and Oxidative stress with Vildagliptin , Nateglinide versus Glimepiride
Not Applicable
- Conditions
- type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000009947
- Lead Sponsor
- Okayama University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1)type 1 diabetes, 2)past history including severe ketosis, diabetic coma or pre-coma wihtin 6 monthes prior to this trial, 3)severe infection, perioperative period, severe trauma, 4) hepatic dysfunction, 5)renal dysfunction, 6)heart failure, 7)oral mediacation except arufa-GI or insulin treatment, 8)steroid treatment, 9)BMI>=28, 10)unstable plasma glucose control(HbA1c>=0.5%/month), 11)pregnant, intention of becoming pregnant, 12)history of anaphylaxis of DPP-4 inhibitor and insulin secretion related drugs, 13)Any other condition which the attending physician feels would interfere with the trail participation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method surrogate marker(inflammation and oxidative stress) after 3 month of treatment
- Secondary Outcome Measures
Name Time Method glycemic control and lipid metabolism, functon of their liver and kidney, sefety evaluation after 3 month of treatment